Please login to the form below

Not currently logged in
Email:
Password:

MedImmune appoints Dr Christopher Rhodes

Will head cardiovascular and metabolic diseaseresearch for the AZ unit

AstraZeneca MedImmune Dr Christopher RhodesAstraZeneca's biologics research and development arm MedImmune has appointed Dr Christopher Rhodes as vice president, cardiovascular and metabolic disease (CVMD) research.

Dr Rhodes will be responsible for developing and growing MedImmune's research base in CVMD in both the US and UK, as well as contributing to the unit's product development goals.

He joins MedImmune from the University of Chicago, where he held a research director's role that covered diabetes, endocrinology and molecular metabolism and nutrition.

In that position he led a large team of researchers focused on molecular mechanisms that control key functions in the pathogenesis of diabetes and obesity.

YongJun Liu, senior vice president of R&D at MedImmune, said: “I am delighted to welcome Dr Rhodes, a world-renowned researcher in the diabetes field, to MedImmune at this extremely exciting time for our Cardiovascular and Metabolic Disease therapeutic area.

“With his wealth of experience, we know he will propel MedImmune to the next level in metabolic disease, guiding our overall CVMD research strategy and driving results to ensure a seamless process for the progression of new drug candidates through the development process, with the ultimate goal of delivering novel medicines to patients.”

10th August 2015

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....